Evidence map›Paper›PMID 27826444›Full record

ArticleMultidisciplinary respiratory medicine2016

Efficacy of recombinant human soluble thrombomodulin for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a single arm, non-randomized prospective clinical trial.

Sho Hayakawa, Yasuo Matsuzawa, Tamako Irie, Hagino Rikitake, Noriaki Okada, Yasuo Suzuki

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multidisciplinary respiratory medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 4 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 4 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Acute exacerbation in fibrotic interstitial lung disease: an international working group report.American journal of respiratory and critical care medicine · 2026
    Review
  7. ARDS Clinical Practice Guideline 2021.Journal of intensive care · 2022
    Article
  8. Article
  9. Article
  10. Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial.American journal of respiratory and critical care medicine · 2020
    Article
  11. Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Call to Arms.American journal of respiratory and critical care medicine · 2020
    Article
  12. Review
  13. Acute Exacerbation of Idiopathic Pulmonary Fibrosis.Medicina (Kaunas, Lithuania) · 2019
    Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Sho HayakawaDepartment of Internal Medicine, Toho University Medical Center, Sakura Hospital, 564-1 Shimoshidu, Sakura City, Chiba 285-8741 Japan.
Yasuo MatsuzawaDepartment of Internal Medicine, Toho University Medical Center, Sakura Hospital, 564-1 Shimoshidu, Sakura City, Chiba 285-8741 Japan.ORCID 0000-0001-7470-6303
Tamako IrieDepartment of Internal Medicine, Toho University Medical Center, Sakura Hospital, 564-1 Shimoshidu, Sakura City, Chiba 285-8741 Japan.
Hagino RikitakeDepartment of Internal Medicine, Toho University Medical Center, Sakura Hospital, 564-1 Shimoshidu, Sakura City, Chiba 285-8741 Japan.
Noriaki OkadaDepartment of Internal Medicine, Toho University Medical Center, Sakura Hospital, 564-1 Shimoshidu, Sakura City, Chiba 285-8741 Japan.
Yasuo SuzukiDepartment of Internal Medicine, Toho University Medical Center, Sakura Hospital, 564-1 Shimoshidu, Sakura City, Chiba 285-8741 Japan.
Toho University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCoagulation abnormalities are involved in the pathogenesis of acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF). The administration of recombinant human soluble thrombomodulin (rhTM), which has both anti-inflammatory and anticoagulant activities, improves outcomes and respiratory function in patients with acute respiratory distress syndrome. Therefore, we conducted a prospective clinical study to examine the effects of rhTM on respiratory function, coagulation markers, and outcomes for patients with AE-IPF.

methodsAfter registration of the protocol, the patients with AE-IPF who satisfied the study inclusion criteria were treated daily with 380 U/kg of rhTM for 7 days and steroid pulse therapy. The concomitant administration of immunosuppressants and polymyxin B-immobilized fiber column treatment was prohibited. The sample size was 10 subjects. The primary study outcome was the improvement of PaO

resultsThe mean PaO

conclusionrhTM plus steroid pulse therapy improves respiratory functions in patients with AE-IPF and is expected to improve overall patient survival without using other combination therapies.

trial registrationThe study was registered with University Hospital Medical Information Network Clinical Trial Registry (UMIN-CTR) in October 2012 (UMIN000009082).

Indexed as

Acute exacerbationIdiopathic pulmonary fibrosisRecombinant human soluble thrombomodulin

Identifiers

PMID27826444
PMCPMC5098285
OpenAlexW2521337826

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.